Skip to Content
Merck
All Photos(1)

Documents

H0262

Sigma-Aldrich

HAT Media Supplement (50×) Hybri-Max™

lyophilized powder, suitable for hybridoma, BioXtra

Synonym(s):

HAT Supplement, Hypoxanthine-Aminopterin-Thymidin (HAT) media supplement

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

UNSPSC Code:
12352207
NACRES:
NA.75

product name

HAT Media Supplement (50×) Hybri-Max™, γ-irradiated, lyophilized powder, BioXtra, suitable for hybridoma

sterility

γ-irradiated

product line

BioXtra

form

lyophilized powder

technique(s)

cell culture | hybridoma: suitable

impurities

endotoxin, tested

shipped in

dry ice

storage temp.

−20°C

Related Categories

Application

HAT Media Supplement (50×) Hybri-Max™ has been used:
  • in the selection and validation of hypoxanthine-guanine phosphoribosyltransferase (HPRT)-deficient clones
  • in the generation of mAbs (monoclonal antibodies)
  • in the luciferase-based bioassay (LUC) assay

Reconstitution

Reconstitute contents of vial with 10 ml sterile cell culture medium. Stock solution is sufficient to prepare 500 ml medium. Final working concentration: 100 μM hypoxanthine, 0.4 μM aminopterin, 16 μM thymidine.

Legal Information

Hybri-Max is a trademark of Sigma-Aldrich Co. LLC

Pictograms

Health hazardExclamation mark
GHS08,GHS07

Signal Word

Danger

Hazard Statements

H302,H360FD

Hazard Classifications

Acute Tox. 4 Oral - Repr. 1B

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Geoffrey A Mueller et al.
Journal of immunology (Baltimore, Md. : 1950), 205(8), 1999-2007 (2020-09-11)
IgE Abs drive the symptoms of allergic disease upon cross-linking allergens on mast cells or basophils. If the IgE binding sites on the allergens could be identified, it may be useful for creating new forms of immunotherapy. However, direct knowledge
J H Connolly et al.
Journal of anatomy, 195 ( Pt 2), 161-171 (1999-10-21)
The gross and histological appearance and the distribution of T and B lymphocytes and plasma cells are described for lymphoid tissues obtained from 15 platypuses. The spleen was bilobed and surrounded by a thick capsule of collagen, elastic fibres and
Development and validation of cell-based luciferase reporter gene assays for measuring neutralizing anti-drug antibodies against interferon beta
Hermanrud C, et al.
Journal of Immunological Methods, 1-9 (2016)
Youngkyun Kim et al.
Clinical & translational immunology, 4(11), e51-e51 (2015-12-19)
This study was undertaken to develop a novel anti-citrullinated peptide antibody (ACPA) and to investigate its arthritogenicity in a collagen-induced arthritis (CIA) model. The novel ACPA, 12G1, was developed by injecting cyclic citrullinated antigen in mice and subsequently hybridizing the
Renjian Hu et al.
Viruses, 12(3) (2020-03-25)
At present, the clinical detection method of human papillomavirus (HPV) is mainly based on the PCR method. However, this method can only be used to detect HPV DNA and HPV types, and cannot be used to accurately predict cervical cancer.
View All Related Papers

Related Content

Monoclonal Antibody Production and Purification

Major technological advances have made the production of monoclonal antibodies quicker and more efficient. There are three established platforms for antibody discovery. We offer reagents for production of monoclonal antibody libraries using each of these techniques.

Monoclonal Antibody Production and Purification

Major technological advances have made the production of monoclonal antibodies quicker and more efficient. There are three established platforms for antibody discovery. We offer reagents for production of monoclonal antibody libraries using each of these techniques.

Monoclonal Antibody Production and Purification

Major technological advances have made the production of monoclonal antibodies quicker and more efficient. There are three established platforms for antibody discovery. We offer reagents for production of monoclonal antibody libraries using each of these techniques.

Monoclonal Antibody Production and Purification

Major technological advances have made the production of monoclonal antibodies quicker and more efficient. There are three established platforms for antibody discovery. We offer reagents for production of monoclonal antibody libraries using each of these techniques.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service